RegulationFast Track (United States), Orphan Drug (United States), Qualified Infectious Disease Product (United States), Orphan Drug (European Union), Priority Review (United States)

Structure/Sequence

Molecular FormulaC50H75N5O11

InChIKeyWKIRTJACGBEXBZ-FQGZCCSZSA-N

CAS Registry1965291-08-0

Clinical Trials associated with Ibrexafungerp Citrate

EUCTR2024-000382-25-3RD

Phase 1

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Ibrexafungerp (SCY-078) in Adolescent Female Subjects

Start Date25 Sep 2024

Sponsor / Collaborator

SCYNEXIS, Inc.

NCT06954493

/ CompletedPhase 1

Phase 1, Open-Label Pharmacokinetic Study in Healthy Lactating Women After Two Oral Doses of Ibrexafungerp Administered on a Single Day

This is a pharmacokinetic evaluation of lactating women after receiving two doses of Ibrexafungerp. The study population included healthy lactating females who were at least 10 days postpartum with a fully established milk supply and were between the ages of 18 and 50 years at the time of screening

Start Date12 Jul 2023

Sponsor / Collaborator

SCYNEXIS, Inc.

CTR20223058

/ SuspendedPhase 3

一项在念珠菌血症和/或侵袭性念珠菌病患者中比较两项治疗方案（静脉注射棘白菌素后口服Ibrexafungerp 和静脉注射棘白菌素后口服氟康唑）的III 期、多中心、前瞻性、随机、双盲研究（MARIO）

[Translation] A phase III, multicenter, prospective, randomized, double-blind study comparing two treatment regimens (IV echinocandin followed by oral ibrexafungerp vs. IV echinocandin followed by oral fluconazole) in patients with candidemia and/or invasive candidiasis (MARIO)

主要研究目的：在念珠菌血症和/或侵袭性念珠菌病患者中，评估IV 棘白菌素后口服Ibrexafungerp 第30 天的全因死亡率（All Cause Moritality, ACM）非劣效于IV 棘白菌素后口服氟康唑的治疗方案；关键次要研究目的：在念珠菌血症和/或侵袭性念珠菌病患者中，评估IV 棘白菌素后口服Ibrexafungerp 第14 天的总体应答率（经数据审查委员会 [Data Review Committee, DRC] 判定的临床、影像学和真菌学方面的综合应答）非劣效于IV 棘白菌素后口服氟康唑的治疗方案；其他次要目的：根据第30天和抗真菌治疗结束时的总体应答、临床应答、真菌学应答、无复发、患者存活且真菌学清除指标来评估有效性；评估IV棘白菌素后口服Ibrexafungerp治疗的安全性；评估Ibrexafungerp的药代动力学（PK）特征。

[Translation]

The primary study objective was to evaluate the non-inferiority of oral ibrexafungerp after IV echinocandin to oral fluconazole in terms of all-cause mortality (ACM) at day 30 in patients with candidemia and/or invasive candidiasis. The key secondary study objective was to evaluate the non-inferiority of oral ibrexafungerp after IV echinocandin to oral fluconazole at day 14 in patients with candidemia and/or invasive candidiasis (composite clinical, radiological, and mycological responses as assessed by the Data Review Committee [DRC]). Other secondary objectives were to evaluate the efficacy based on overall response, clinical response, mycological response, freedom from relapse, patient survival, and fungal clearance at day 30 and at the end of antifungal treatment; to evaluate the safety of oral ibrexafungerp after IV echinocandin; and to evaluate the pharmacokinetic (PK) characteristics of ibrexafungerp.

Start Date18 Mar 2023

Sponsor / Collaborator

SCYNEXIS, Inc.

[+1]

100 Clinical Results associated with Ibrexafungerp Citrate

100 Translational Medicine associated with Ibrexafungerp Citrate

100 Patents (Medical) associated with Ibrexafungerp Citrate

131

Literatures (Medical) associated with Ibrexafungerp Citrate

01 Dec 2025·Journal of Global Antimicrobial Resistance

In vitro evaluation of Ibrexafungerp against clinical and environmental isolates of cryptococcus neoformans and cryptococcus gattii

Letter

Author: Firacative, Carolina ; Ceballos-Garzon, Andrés

01 Dec 2025·Drugs-Real World Outcomes

Real-World Ibrexafungerp Use Patterns Among Patients with Commercial Health Insurance, United States, 2021–2023

Article

Author: Benedict, Kaitlin ; Gold, Jeremy A W ; Smith, Dallas J

Abstract:

Background:

Vulvovaginal candidiasis (VVC) is a common gynecological complaint. Ibrexafungerp (brand name: Brexafemme®) is a new, first-in-class oral antifungal medication approved as a 1-day treatment for VVC and as a monthly treatment to reduce frequency of recurrent VVC.

Objective:

This article describes characteristics of patients who received ibrexafungerp and potential ibrexafungerp-related side effects in order to help inform optimal future use of this medication.

Methods:

We used a large, national commercial health insurance claims database (the Merative TM MarketScan® Commercial/Medicare Database) to identify female patients with one or more outpatient ibrexafungerp prescription during 1 July 2021 to 31 December 2023. We examined patient demographic characteristics, medical conditions and medications, type of healthcare provider seen, diagnostic testing performed, and potential ibrexafungerp side effects.

Results:

Among 1368 female patients who received ibrexafungerp, most were also prescribed fluconazole or topical antifungals (84.7%) or had one or more vaginitis/vulvitis-related healthcare visit (76.9%) in the previous year. Few patients (2.9%) experienced a potential ibrexafungerp-related side effect.

Conclusions:

Our results suggest that ibrexafungerp was generally used as non-first-line treatment for VVC.

01 Dec 2025·AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis

Article

Author: Angulo, David A ; Nyirjesy, Paul ; Azie, Nkechi E ; Sobel, Ryan ; Sobel, Jack D ; Goje, Oluwatosin

BACKGROUND:

Recurrent vulvovaginal candidiasis develops in 5% to 9% of people assigned female at birth and has a serious impact on quality of life. Oral ibrexafungerp is a first-in-class, nonazole, triterpenoid antifungal approved in the United States for the treatment of postmenarchal females with acute vulvovaginal candidiasis and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

OBJECTIVE:

This phase 3 study (CANDLE) describes the efficacy and safety of monthly oral ibrexafungerp vs placebo for reducing the incidence of recurrent vulvovaginal candidiasis.

STUDY DESIGN:

Participants with a history of recurrent vulvovaginal candidiasis experiencing an acute infection episode (confirmed by positive potassium hydroxide test) received 3 doses of oral fluconazole (150 mg once-daily every 3 days). Those who had culture-confirmed vulvovaginal candidiasis from the screening sample achieved substantial resolution of signs and symptoms (composite Vulvovaginal Signs and Symptoms score≤2) following fluconazole treatment and continued to meet all study eligibility criteria, entered a maintenance phase. In the maintenance phase, eligible participants were randomized (1:1) to oral ibrexafungerp (300 mg twice-daily for 1 day) or placebo, which was repeated once every 4 weeks for a total of 6 treatments (until week 20). Efficacy was assessed by the percentage of participants with no mycologically proven recurrence and the percentage of participants with clinical success (a participant with a Test-of-Cure [week 24] evaluation and no recurrence; mycologically proven, presumed, or suspected) by Test-of-Cure (4 weeks after last study drug dose). Safety and tolerability assessments included incidence of adverse events and treatment discontinuations. Participants were further assessed for recurrence during a 12-week follow-up phase.

RESULTS:

In the intent-to-treat population, 70.8% (n=92/130) of participants who received ibrexafungerp and 58.5% (n=76/130) who received placebo had no mycologically proven recurrence by Test-of-Cure (relative risk, 1.22; 95% confidence interval, 1.032, 1.430; P=0.019). The proportion of participants who achieved clinical success by Test-of-Cure was 65.4% (n=85/130) with ibrexafungerp and 53.1% (n=69/130) with placebo (relative risk, 1.24; 95% confidence interval, 1.034, 1.486; P=0.020). The benefit of ibrexafungerp over placebo was sustained over the 4 months following last study drug dose for both the no mycologically proven recurrence (65.4% [n=85/130] vs 53.8% [n=70/130]; relative risk, 1.22; 95% confidence interval, 1.021, 1.456; P=0.029) and clinical success (57.7% [n=75/130] vs 46.2% [n=60/130]; relative risk, 1.26; 95% confidence interval, 1.017, 1.555; P=0.034) endpoints. Overall, 64.6% (n=84/130) of participants who received ibrexafungerp and 58.5% (n=76/130) of participants who received placebo experienced ≥1 treatment-emergent adverse event. Treatment-related adverse events occurred in 14.6% (n=19/130) of participants in the ibrexafungerp group and 6.9% (n=9/130) of participants in the placebo group. No adverse events in the ibrexafungerp group led to treatment or study discontinuation. The most common adverse events reported in both the ibrexafungerp and placebo groups were headache, bacterial vaginosis, and diarrhea; these events were mostly mild in severity.

CONCLUSION:

Once-monthly oral ibrexafungerp was effective and well-tolerated in participants with recurrent vulvovaginal candidiasis.

141

News (Medical) associated with Ibrexafungerp Citrate

22 Dec 2025

·www.globenewswire.com

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). The Company now has until June 15, 2026, to meet the requirement for its shares of common stock to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. Nasdaq granted the extension after determining that SCYNEXIS continues to meet all other continued listing criteria for the Nasdaq Capital Market, including the market value of publicly held shares, and has provided written notice of its intention to cure the deficiency within the extension period, if necessary, through a reverse stock split. “We are grateful for Nasdaq’s decision to grant this 180-day extension, which allows us to continue advancing our strategic objectives,” said David Angulo, M.D., President and Chief Executive Officer. “In the upcoming year we expect to leverage our balance sheet to complete a Phase 1 study of an intravenous (IV) formulation for our next-generation fungerp, SCY-247, as well as generate proof-of-concept Phase 2 data in the oral formulation of SCY-247 for invasive candidiasis infections. SCY-247 is an exciting investigational antifungal with the potential to benefit both hospitalized and community patients with challenging infections and is highly anticipated by the anti-infective scientific community. Lastly, SCYNEXIS remains committed to full compliance with all Nasdaq listing requirements and plans to take all necessary actions within the prescribed 180-day period to regain compliance.” About SCYNEXIS SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) has approved BREXAFEMME® (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC. Additional antifungal assets from this novel class are currently in clinical, pre-clinical and discovery phases, including the compound SCY-247. For more information, visit www.scynexis.com. Forward-Looking Statements Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: regaining Nasdaq compliance, completing a Phase 1 study of an IV formulation for SCY-247, generating proof-of-concept Phase 2 data in the oral formulation of SCY-247 for invasive candidiasis infections, and the potential benefits of SCY-247. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 12, 2025, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. CONTACT: Investor RelationsIrina KofflerLifeSci AdvisorsTel: 917-734-7387ikoffler@lifesciadvisors.com

Phase 1Drug ApprovalPhase 2

19 Nov 2025

·www.globenewswire.com

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the transfer of the BREXAFEMME (ibrexafungerp) New Drug Application (NDA) to GSK. “We are pleased to announce this important milestone for SCYNEXIS. With the transfer of the BREXAFEMME NDA now complete, GSK will be able to initiate regulatory interactions with the U.S. Food and Drug Administration (FDA) to discuss the relaunch of BREXAFEMME for vulvovaginal candidiasis (VVC) and refractory vulvovaginal candidiasis (rVVC) in the U.S. market,” said David Angulo, M.D., President and Chief Executive Officer. “Furthermore, SCYNEXIS stands to receive net sales milestones and royalties following the relaunch providing a significant future source of non-dilutive capital.” About SCYNEXIS SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) has approved BREXAFEMME® (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC. Additional antifungal assets from this novel class are currently in clinical, pre-clinical and discovery phases, including the compound SCY-247. For more information, visit www.scynexis.com. Forward-Looking Statements Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: receipt of milestones and royalties from GSK. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 12, 2025, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. CONTACT: Investor RelationsIrina KofflerLifeSci AdvisorsTel: 917-734-7387ikoffler@lifesciadvisors.com

Drug ApprovalNDALicense out/inAcquisition

17 Nov 2025

·ir.scynexis.com

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation of triterpenoid antifungals (fungerps). Next-generation fungerps, in preclinical stages of development, are targeted to have enhanced pharmacological properties to treat fungal infections where current therapies are limited or not effective, while maintaining broad spectrum of activity against resistant fungal pathogens. JERSEY CITY, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that a novel series of antifungal compounds utilizing SCYNEXIS’ proprietary triterpenoid antifungal platform are among the five projects funded by the federal grant awarded to the new accelerator consortium led by researchers from Hackensack Meridian Center for Discovery and Innovation (CDI) and the Johns Hopkins Bloomberg School of Public Health. A five-year federal grant will establish a Center of Excellence in Translational Research (CETR) jointly between researchers from the Bloomberg School and the CDI, and other academic and commercial collaborators. The CETR expects to receive about $7 million annually, contingent upon the availability of funds, with the support coming from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID). “With approximately four million annual deaths attributable to fungal infections globally1, this new grant from the NIH provides essential funding to support the development of new therapeutics that can address the growing threat from resistant fungal infections,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. “As part of this research collaboration, we are pleased to note that a series of next-generation fungerp candidates are included, with the aim to progress their development from early preclinical stage to IND ready candidates. For this collaboration we have selected a few fungerps with key attributes including activity against resistant fungi and differentiated pharmacological properties, critical for addressing significant limitations of currently available antifungal armamentarium. We are very pleased to collaborate with this CETR in tackling one of the world’s most pressing health threats.” 1 https://scienceline.org/2025/01/fungal-infections-treatment-options/ About Triterpenoid Antifungals (Fungerps) Triterpenoid antifungals (fungerps) are a novel class of structurally-distinct glucan synthase inhibitors being developed to address the significant threat posed by antimicrobial resistance (AMR) in systemic fungal diseases with high mortality. The triterpenoid class of antifungals represents the first new class of antifungal compounds approved since 2001. These agents combine the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) in 2021 and for reduction in the incidence of recurrent VVC in 2022. SCY-247 is a second-generation fungerp, in Phase 1 of development and has demonstrated in vitro and in vivo broad-spectrum antifungal activity, including against multidrug resistant fungal pathogens. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phases of development. About the Center for Discovery and Innovation The Center for Discovery and Innovation, a member of Hackensack Meridian Health, translates current innovations in science to improve clinical outcomes for patients. More than 34 laboratories, 200+ professional researchers and physician-scientists at the CDI have set their sights on cancer, infectious diseases, autoimmune disorders, and other acute and chronic diseases. Clinical need drives scientific insights and their application for these researchers, leading to the development of new diagnostics, therapies, and surveillance capabilities in response to emerging health challenges. The CDI harnesses cutting-edge advances in genetics, molecular biology, clinical immunology, imaging, and behavioral sciences to better diagnose, treat and prevent disease through personalized medicine approaches. For additional information, please visit www.hmh-cdi.org. About SCYNEXIS SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” For more information, visit www.scynexis.com. Forward-Looking Statements Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: SCYNEXIS’ anticipation that the U.S. Food and Drug Administration (FDA) may grant SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track designations for both the IV and oral formulations of SCY-247. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 12, 2025, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. CONTACT: Investor Relations Irina Koffler LifeSci Advisors Tel: 917-734-7387 ikoffler@lifesciadvisors.com Released November 17, 2025

Drug ApprovalPhase 1Fast TrackQualified Infectious Disease Product

100 Deals associated with Ibrexafungerp Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D11544	-	J02AX	DB12471

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Candidiasis, Vulvovaginal	United States	GlaxoSmithKline LLC	01 Jun 2021
Candidiasis, Vulvovaginal	United States	Glaxosmithkline Plc /Suzhou Mfg. Facility/	01 Jun 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Candida Auris Infection	Phase 3	United States	SCYNEXIS, Inc.	15 Nov 2017
Candida Auris Infection	Phase 3	India	SCYNEXIS, Inc.	15 Nov 2017
Candida Auris Infection	Phase 3	Pakistan	SCYNEXIS, Inc.	15 Nov 2017
Candida Auris Infection	Phase 3	South Africa	SCYNEXIS, Inc.	15 Nov 2017
Candidemia	Phase 3	United States	SCYNEXIS, Inc.	15 Nov 2017
Candidemia	Phase 3	India	SCYNEXIS, Inc.	15 Nov 2017
Candidemia	Phase 3	Pakistan	SCYNEXIS, Inc.	15 Nov 2017
Candidemia	Phase 3	South Africa	SCYNEXIS, Inc.	15 Nov 2017
Aspergillosis, Allergic Bronchopulmonary	Phase 3	United States	SCYNEXIS, Inc.	01 Apr 2017
Aspergillosis, Allergic Bronchopulmonary	Phase 3	Austria	SCYNEXIS, Inc.	01 Apr 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06954493 (CTgov)	Phase 1	Candidiasis, Vulvovaginal	5	Ibrexafungerp	cqhiseisah(uydcjobavj) = qqfweslmuc xkxyinnywj (kzuyloutxr, sgmgdkvzlx - twadxqzgcl) View more	-	08 Aug 2025
NCT03059992 (FURI, CTgov)	Phase 3	Candidiasis, Vulvovaginal \| Coccidioidomycosis \| Histoplasmosis ... View more	233	Ibrexafungerp	fhpcqyoryx(gsrpoctuth) = tmckyvbroi qsknfoajdl (tesvpvefnr, bsrshbbgvx - mhqudyseer) View more	-	20 Nov 2024
CTR20220918 (Pubmed \| Infection) Manual	Phase 3	Candidiasis, Vulvovaginal	360	IbrexafungerpIbrexafungerp 300 mg	dmtqfcaqum(nakexxomqs) = gcpnuptmev jtdaimaxqe (qxpoxyoovh ) View more	Positive	01 Oct 2024
				Placebo	dmtqfcaqum(nakexxomqs) = ywayclbnrj jtdaimaxqe (qxpoxyoovh ) View more
NCT03672292 (SCYNERGIA, CTgov)	Phase 2	Invasive Pulmonary Aspergillosis	22	Voriconazole+SCY-078 (SCY-078 Plus Voriconazole)	skydjowddr = sehfufxibv xdvjuzvfrs (hfqgklkoms, eumlhtmxmq - axeqkrsczu) View more	-	09 Aug 2024
				Oral Placebo Tablets+Voriconazole (Voriconazole Mono-therapy)	skydjowddr = fbzpqqdhrp xdvjuzvfrs (hfqgklkoms, ogyfntjcya - elfvuskavw) View more
NCT05399641 (CTgov)	Phase 3	Candidiasis, Vulvovaginal	150	Ibrexafungerp (Group A)	qjkpbonilu = vajrxmapqv ikpgwehmce (ksmvsxnyns, faprksyiqr - hyvtnffghu) View more	-	10 Jul 2024
				Ibrexafungerp (Group B (3 Day Dosing))	qjkpbonilu = mmjnsqmgqn ikpgwehmce (ksmvsxnyns, tnbehswzfk - ullugpsbhj) View more
NCT03363841 (CARES, CTgov)	Phase 3	Candida Auris Infection \| Candidemia	30	Ibrexafungerp	qiuxuexohz = zhgghbkkxi qmrveyqbqi (frchaqyrtx, vxrqsxilgv - yroqypioxs) View more	-	03 Jul 2024
NCT02244606 (CTgov)	Phase 2	Candidemia	27	Ibrexafungerp (Ibrexafungerp 500-mg)	nvjrnjovjv = ikyuqtlmvk htcawgsmnw (ygkghqjzzo, olaemuktcx - smmfpreuuy) View more	-	25 Jun 2024
				Ibrexafungerp (Ibrexafungerp 750-mg)	nvjrnjovjv = bbeyvcubzc htcawgsmnw (ygkghqjzzo, plgmjmlszz - jrdzimlafm) View more
NCT04029116 (CANDLE, CTgov)	Phase 3	Candidiasis, Vulvovaginal	440	Fluconazole Tablet+IBREXAFUNGERP (Ibrexafungerp)	zjwmejufec = hvenbiesdl muthxtmrzq (ypskqdwsxp, qfchjlxlbw - pnrvjtwvtq) View more	-	18 Jun 2023
				Placebo oral tablet+Fluconazole Tablet (Placebo)	zjwmejufec = luszwpikaw muthxtmrzq (ypskqdwsxp, mumvrzraid - kamsmvopfb) View more
NCT03734991 (VANISH 303 and VANISH 306, Pubmed \| J Womens Health (Larchmt))	Phase 3	Candidiasis, Vulvovaginal	376	Ibrexafungerp 300mg BID	pqxotjdzkh(rxcwfahujx) = ghbjwfvcgx oonkwlzidc (zltrrgmclu ) View more	-	17 Oct 2022
				Placebo	pqxotjdzkh(rxcwfahujx) = cgmnsexvxb oonkwlzidc (zltrrgmclu ) View more
NCT03363841 (CARES, Biospace) Manual	Phase 3	Candidiasis	18	Ibrexafungerp	ixnorrmmmi(wwtkvtqrrt) = fqusegrijg ytiejdmtxs (tapojisgfb ) View more	Positive	08 Sep 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis